High-risk Antithrombotic Drugs at Discharge and Consultation for Hemorrhagic or Thromboembolic Events in the Emergency Department

NCT07278648 | Not Yet Recruiting

• 1 other identifier: CSAPG-79
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

This observational study aims to estimate the proportion of patients discharged from a hospital with a prescription for anticoagulant medication who subsequently visit the emergency department due to an adverse thrombotic or hemorrhagic event related to the treatment.

Conditions

Acute Disease

Keywords

Antithrombotic Treatment; Hemorragic Event; Anticoagulants

Outcome Measures

Primary Outcomes (1)

• Hemorragic event

  Proportion of patients who experience a hemorrhagic event within 90 days of hospital discharge

  Day 90 from baseline

Study Arms (1)

Anticoagulant therapy

Patients who has been discharged from hospital with anticoagulant therapy

Other: Antithrombotic therapy

Interventions

Antithrombotic therapy OTHER

Anticoagulant treatment prescribed at discharge from an acute care unit

Anticoagulant therapy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who has been discharged from an acute care unit with anticoagulant therapy

You may qualify if:

• Patients discharged from the Emergency Department (ED) and acute care units with an electronic prescription for at least one anticoagulant medication (new or ongoing), identified with the following codes:
• B01AA - Vitamin K antagonists: warfarin and acenocoumarol
• B01AB - Heparin group: low-molecular weight heparins such as enoxaparin, tinzaparin, bemiparin, …
• B01AE - Direct thrombin inhibitors: dabigatran
• B01AF - Direct factor Xa inhibitors: rivaroxaban, apixaban, edoxaban

You may not qualify if:

• Those who are not part of the CSAPG healthcare area.
• Patients discharged from outpatient clinics, home hospitalization units, intermediate care, or residential facilities.

Sponsors & Collaborators

• Consorci Sanitari de l'Alt Penedès i Garraf: lead

Study Sites (1)

Hospital de Vilafranca

Vilafranca del Penedès, Barcelona, 08720, Spain

Location

MeSH Terms

Conditions

Acute Disease

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Mar Saavedra

CONTACT

0034938960025; msaavedra@csapg.cat

Noemí Casaponsa

CONTACT

0034938960025; recerca@csapg.cat

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 1, 2025
• First Posted: December 12, 2025
• Study Start: February 5, 2026
• Primary Completion: March 1, 2026
• Study Completion: March 1, 2026
• Last Updated: December 24, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After publication of main results of the study.
• Access Criteria: IPD will be shared only for scientific research purposes and following the Spanish and European Union normative law about data protection. The requirements will be directed to the IP of the study. The IP will evaluate the request to verify and evaluate the data that is requested and the purposes for which it is requested. Next, the IP will transfer the request to the promotor center the study for the final decision.

Locations

ES (1)